| Name | Sudoxicam |
| Description | Sudoxicam (4-Hydroxy-2-methyl-N-2-thiazolyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide) is a reversible antagonist of COX with anti-inflammatory, anti-edema, and antipyretic properties. |
| In vitro | Sudoxicam binds covalently to NADPH-dependent human liver microsomes. When glutathione (GSH) was added to the microsomal incubation, about half of the covalent binding of sudoxicam was blocked by glutathione[1]. |
| In vivo | Sudoxicam (0.1 mg/kg, p.o) significantly inhibits edema formation. In rats, Sudoxicam (1, 3.3 and 10 mg/kg; orally) effectively reduces plasma inflammation units, decreases the inflamed hind-paws swelling and restores toward normal the daily gain in body weight. Sudoxicam (3.3 mg/kg, i.p.) counteracts the pyrexia induced by the intraperitoneal injection of typhoid/paratyphoid vaccine and maintains body temperature. In the guinea pig, Sudoxicam inhibits the erythema caused by ultraviolet irradiation. The plasma half-life of Sudoxicam is 8, 13 and hours for monkey, rat and dog[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 80 mg/mL (237.13 mM), Sonication and heating to 80℃ are recommended.
|
| Keywords | Sudoxicam |
| Inhibitors Related | Ibuprofen | Acetaminophen | Salicylamide | Diclofenac sodium | Diclofenac Potassium | Paradol | Indomethacin sodium hydrate | Trometamol | Glafenine | Revaprazan hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Neuronal Signaling Compound Library | ReFRAME Related Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
